Data from the French Daily-Luma cohort suggest predictors of a lumasiran response.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soncin Vittoria, Sellier Leclerc Anne Laure, Acquaviva-Bourdain Cécile, Loppinet Thomas, Boyer Olivia, Knebelmann Bertrand, Allard Lise, Dossier Claire, Cloarec Sylvie, Stehlé Thomas, Nobili François, Courbebaisse Marie, Vrillon Isabelle, Ducret Maize, Zaloszyc Ariane, Le Quintrec Moglie, Casado Edouard Martinez, Krummel Thierry, Rousset-Rouviere Caroline, Burtey Stéphane, Ryckewaert Amélie, Frouget Thierry, Di Maio Massimo, Samaille Charlotte, Cornec-Le Gall Emilie, Hanf William, Monet-Didailler Catherine, Schendel Adeline, Garnier Arnaud, Pons Aurélie, Snanoudj Renaud, Cherni Nadia, Fila Marc, Faudeux Camille, Mauras Mathilde, Mohamadou Inna, Lemoine Sandrine, Bacchetta Justine
Аннотация
METHODS: In the ongoing French DAILY-LUMA cohort evaluating real-life efficacy and safety of lumasiran, we collected data at treatment initiation and at months three, six and 12 of treatment. The main outcomes were composite criteria, namely normalization and/or reduction over 30% from baseline in the urinary ratio of oxalate and creatinine (UOx/Creat) or in blood oxalate levels (POx) in patients with estimated glomerular filtration rate (eGFR) over or under 30 mL/min/1.73 m2, respectively. The primary endpoint was the proportion of patients reaching this criterion at three months, and secondary endpoints were the same analysis at six and 12 months. Genotype was classified into three groups depending on the vitamin B6 response: resistance, sensitivity, uncertain response (Ile244Thr variant of alanine-glyoxylate aminotransferase).
RESULTS: In total, 76 patients (54 children) were included, at a median (inter quartile range) age at lumasiran initiation of 13 (4-33) years with 24 patients on dialysis. After three months treatment, 73 % of patients met the primary endpoint (% calculated on available data). There was no significant association between the underlying genotype and lumasiran response, albeit with a trend towards a lesser response in vitamin B6- sensitive forms. The only significant determinants found to be associated with the primary outcome were age at diagnosis and age at lumasiran initiation, the best response being observed in pediatric patients.
CONCLUSION: Our study suggests a better response to lumasiran in children independent of the underlying genotype. In patients with pyridoxine sensitivity, we suggest continuing or initiating pyridoxine even after lumasiran initiation. After lumasiran initiation, a close follow-up and re-evaluation should be systematically performed.